| Drug name | Bapineuzumab |
| Phase | III |
| Indication | Alzheimer’s disease |
| Pharmacology | Humanized monoclonal IgG1 antibody against the β-amyloid (Aβ) N- terminus(Aβ1–5), based on the murine antibody 3D6 and intended to promote Aβ clearance from the brain |
| Route of administration | Intravenous |
| Pivotal trials | Phase II [1,53], Phase III (NCT00575055 and NCT00574132) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.